Naxaprostene (CG 4305) is a prostacyclin analogue, which causes concentration dependent inhibition of thrombocyte function. Naxaprostene is more selective for IP receptors and tends towards partial agonism. Naxaprostene prevented thrombotic arterial occlusion in rabbits.

Dicirenone is an aldosterone antagonist. It is used as a hypotensive agent. Dicirenone inhibited the effects of aldosterone on urinary K(+):Na(+) ratios and the binding of [(3)H]aldosterone to renal cytoplasmic and nuclear receptors. Dicirenone blocked the action of aldosterone on Na-K ATPase. Cytoplasmic binding of [(3)H]aldosterone and dicirenone was similar in magnitude and involved the same set of sites. It had no effect on adrenal steroidogenesis.

Mesulergine, an antagonist of 5-HT2C, and dopamine receptors was studied in clinical trials for the treatment of Parkinson's disease. However, further, development was discontinued due to toxicological observations in animal experiments.

Feloprentan is an endothelin receptor antagonist.

Cycliramine is a substituted piperidine derivative discovered by Schering Corp. The drug is claimed to have antihistamine, antispasmodic, antiacetylcholine and analgesic activity.

Metaterol is a beta-adrenoceptor agonist. It exerts sympathomimetic and broncholytic properties.

Cinaproxen is naproxen derivative developed by Nicox S.A. for oxidative stress prevention and treatment.

Dexproxibutene is an experimental agent structurally related to propoxyphene. It is an analgesic agent. Dexproxibutene is not very effective in rheumatoid arthritis pain relief. It is intermediate in effectiveness between distalgesic, codis, aspirin and placebo.

Esorubicin (4'-deoxydoxorubicin, NSC 267469) is a synthetic derivative of the anthracycline antineoplastic antibiotic doxorubicin with potential antineoplastic activity. Esorubicin intercalates into DNA and inhibits topoisomerase II, thereby inhibiting DNA replication and ultimately, interfering with RNA and protein synthesis. This agent exhibits less cardiotoxicity than the parent antibiotic doxorubicin, but may cause more severe myelosupression compared to other compounds within the anthracycline class. Esorubicin was being clinically tested for the treatment of solid tumors as well as lymphomas an leukemias. Esorubicin development has been discontinued.